Global Autoimmune Disorder Drug Delivery Devices Market

Focus on Product Type, Indication, Manufacturing Type, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030

Published Year: 2020
SKU: BHL0986SA

3250

Online Access for 1-3 Users. Permission to Print.


In case you require a hard copy, there will be an additional charge of $500. Please email us at [email protected] with your request.

A quick peek into the report

Table of Contents

Download this TOC  

Request a Sample

1 Technology Definition

1.1    Inclusion and Exclusion Criteria
         1.1.1    Inclusions
         1.1.2    Exclusions

2 Research Scope

2.1    Key Questions Answered in the Report

3 Research Methodology

3.1    Autoimmune Disorder Drug Delivery Devices Market: Research Methodology
3.2    Primary Data Sources
3.3    Secondary Data Sources
3.4    Market Estimation Model
3.5    Criteria for Company Profiling

4 Market Overview

4.1    Historic Overview and Future Scope of Injectable Drug Delivery Devices
4.2    Pre-Filled Syringes Manufacturing and Packaging Challenges
4.3    Global Autoimmune Disorder Drug Delivery Devices Market and Growth Potential, 2019-2030
4.4    Pricing and Reimbursement Scenario
4.5    Impact of Patent Expiry and Entry of Biosimilars on Autoimmune Disorder Drug Delivery Devices Market
4.6    Impact of COVID-19 on Autoimmune Disorder Drug Delivery Devices Market

5 Industry Insights

5.1    Overview
5.2    Legal Requirements and Frameworks Across the Globe
5.3    Regulatory Framework and Government Initiatives
5.4    Legal Requirements and Frameworks in North America
         5.4.1    Food and Drug Administration (FDA)
         5.4.2    Health Canada
5.5    Legal Requirements and Frameworks in Europe
         5.5.1    European Union
5.6    Legal Requirements and Frameworks in Asia-Pacific
         5.6.1    National Medical Products Administration (NMPA)
         5.6.2    Pharmaceutical and Medical Device Agency (PMDA)
         5.6.3    Central Drug Standard Control Organization (CDSCO)

6 Patent Landscape

6.1    Patent Analysis (by Drug Delivery Devices)
6.2    Patent Analysis (by IPC Code)
6.3    Patent Analysis (by Country)
6.4    Patent Analysis (by Company)

7 Market Dynamics

7.1    Overview
7.2    Impact Analysis
7.3    Drivers
         7.3.1    Increased Prevalence of Autoimmune Disorders
         7.3.2    Technological Advancements in the Field of Pre-Filled Syringes
         7.3.3    Rising Geriatric Population
         7.3.4    Surge of Biosimilars and Biologics in the Pharmaceutical Market
         7.3.5    Device Connectivity to Ease Competitive Pressure
7.4    Restraints
         7.4.1    Strict Legal Requirements and Regulations
         7.4.2    Alternative Drug Delivery Technology
7.5    Opportunities
         7.5.1    Providing Injectable Drug Delivery Devices for Untapped Autoimmune Disorders
         7.5.2    Opportunities for Personalizing Treatments in Autoimmune Diseases

8 Global Autoimmune Disorder Drug Delivery Devices Market, (by Indication), $Million, 2019-2030

8.1    Rheumatoid Arthritis
8.2    Psoriasis
8.3    Multiple Sclerosis
8.4    Inflammatory Bowel Diseases
8.5    Systemic Lupus Erythematosus

9 Global Autoimmune Disorder Drug Delivery Devices Market, (by Product), $Million, 2019-2030

9.1    Introduction
9.2    Pen Injectors
9.3    Auto-Injectors
9.4    Pre-filled Syringes
9.5    Vials

10 Global Autoimmune Disorder Drug Delivery Devices Market, (by Manufacturing Type), $Million, 2019-2030

10.1    In-House Manufacturing
10.2    Outsourced Manufacturing

11 Global Autoimmune Disorder Drug Delivery Devices Market, (by Region), $Million, 2019-2030

11.1    Overview
11.2    North America
           11.2.1    U.S.
           11.2.2    Canada
11.3    Europe
           11.3.1    Germany
           11.3.2    U.K.
           11.3.3    France
           11.3.4    Italy
           11.3.5    Spain
           11.3.6    Rest-of-Europe
11.4    Asia-Pacific
           11.4.1    China
           11.4.2    Japan
           11.4.3    India
           11.4.4    South Korea
           11.4.5    Australia
           11.4.6    Rest-of-APAC
11.5    Latin America
           11.5.1    Brazil
           11.5.2    Mexico
           11.5.3    Rest-of-Latin America
11.6    Rest-of-the-World

12 Competitive Landscape

12.1    Key Developments and Strategies
           12.1.1    Regulatory and Legal Developments
           12.1.2    Partnerships, Alliances, and Business Expansions
           12.1.3    Mergers and Acquisitions
12.2    Market Share Analysis

13 Company Profiles

13.1    Overview
13.2    Amgen Inc.
           13.2.1    Company Overview
           13.2.2    Role of Amgen Inc. in Global Autoimmune Disorder Drug Delivery Devices Market
           13.2.3    Financials
           13.2.4    Key Insights about Financial Health of the Company
           13.2.5    SWOT Analysis
13.3    AbbVie Inc.
           13.3.1    Company Overview
           13.3.2    Role of AbbVie Inc. in Global Autoimmune Disorder Drug Delivery Devices Market
           13.3.3    Financials
           13.3.4    Key Insights about Financial Health of the Company
           13.3.5    SWOT Analysis
13.4    Bayer AG
           13.4.1    Company Overview
           13.4.2    Role of Bayer AG in Global Autoimmune Disorder Drug Delivery Devices Market
           13.4.3    Financials
           13.4.4    Key Insight about Financial Health of the Company
           13.4.5    SWOT Analysis
13.5    Biogen Inc.
           13.5.1    Company Overview
           13.5.2    Role of Biogen Inc. in Global Autoimmune Disorder Drug Delivery Devices Market
           13.5.3    Financials
           13.5.4    Key Insights about Financial Health of the Company
           13.5.5    SWOT Analysis
13.6    Bristol-Myers Squibb Company
           13.6.1    Company Overview
           13.6.2    Role of Bristol Myers Squibb Company in the Global Autoimmune Disorder Drug Delivery Devices Market
           13.6.3    Financials
           13.6.4    Key Insights About Financial Health of the Company
           13.6.5    SWOT Analysis
13.7    Eli Lilly & Company
           13.7.1    Company Overview
           13.7.2    Role of Eli Lilly & Company in Global Autoimmune Disorder Drug Delivery Device Market
           13.7.3    Financials
           13.7.4    Key Insights About Financial Health of the Company
           13.7.5    SWOT Analysis
13.8    F. Hoffmann-La Roche Ltd
           13.8.1    Company Overview
           13.8.2    Role of F. Hoffmann-La Roche Ltd. in Global Autoimmune Disorder Drug Delivery Devices Market
           13.8.3    Financials
           13.8.4    Key Insights About Financial Health of the Company
           13.8.5    SWOT Analysis
13.9    GlaxoSmithKline plc
           13.9.1    Company Overview
           13.9.2    Role of GlaxoSmithKline plc in Global Autoimmune Disorder Drug Delivery Devices Market
           13.9.3    Financials
           13.9.4    Key Insights About Financial Health of the Company
           13.9.5    SWOT Analysis
13.10    Johnson & Johnson Services, Inc.
             13.10.1    Company Overview
             13.10.2    Role of Johnson & Johnson Services, Inc. in Global Autoimmune Disorder Drug Delivery Devices Market
             13.10.3    Financials
             13.10.4    Key Insights About Financial Health of the Company
             13.10.5    SWOT Analysis
13.11    Merck KGaA
             13.11.1    Company Overview
             13.11.2    Role of Merck KGaA in Global Autoimmune Disorder Drug Delivery Devices Market
             13.11.3    Financials
             13.11.4    Key Insights About Financial Health of the Company
             13.11.5    SWOT Analysis
13.12    Novartis AG
             13.12.1    Company overview
             13.12.2    Role of Novartis AG in Global Autoimmune Disorder Drug Delivery Devices Market
             13.12.3    Financials
             13.12.4    Key Insights About Financial Health of the Company
             13.12.5    SWOT Analysis
13.13    Sanofi S.A.
             13.13.1    Company Overview
             13.13.2    Role of Sanofi S.A. in Global Autoimmune Disorder Drug Delivery Devices Market
             13.13.3    Financials
             13.13.4    Key Insights About Financial Health of the Company
             13.13.5    SWOT Analysis
13.14    Teva Pharmaceutical Industries Ltd.
             13.14.1    Company Overview
             13.14.2    Role of Teva Pharmaceutical Industries Ltd. in Global Autoimmune Disorder Drug Delivery Devices Market
             13.14.3    Financials
             13.14.4    Key Insight About Financial Health of the Company
             13.14.5    SWOT Analysis
13.15    UCB Pharma SA.
             13.15.1    Company Overview
             13.15.2    Role of UCB Pharma SA in Global Autoimmune Disorder Drug Delivery Devices Market
             13.15.3    Financials
             13.15.4    Key Insight About Financial Health of the Company
             13.15.5    SWOT Analysis

List of Tables

Table 1:    Leading Players in Global Autoimmune Disorder Drug Delivery Devices Market
Table 4.1:    Patent Expiry of Autoimmune Disorder Therapeutics
Table 5.1:    Legal Requirements and Frameworks Across the Globe
Table 7.1:    Deaths Due to Multiple Sclerosis in Key Countries, 2015-2017
Table 7.2:    Filing Requirements for Pre-filled Syringes:
Table 7.3:    Differentiation of an Injectable Therapeutic Throughout its Life Cycle:
Table 7.4:    Alternative Drug Delivery Technologies:
Table 8.1:    Global Autoimmune Disorder Therapeutics Sales, 2017-2019

List of Figures

Figure 1:    Global Prevalence of Rheumatoid Arthritis (1990-2017)
Figure 2:    Global Autoimmune Disorder Drug Delivery Devices Market, ($Million),  2019-2030
Figure 3:    Impact Analysis
Figure 4:    Share of Key Developments and Strategies, (September 2017-September 2020)
Figure 5:    Global Autoimmune Disorder Drug Delivery Devices Market (by Product), ($Million), 2019 and 2030
Figure 6:    Global Autoimmune Disorder Drug Delivery Devices Market (by Indication), ($Million), 2019 and 2030
Figure 7:    Global Autoimmune Disorder Drug Delivery Devices Market (by Manufacturing Type), ($Million), 2019 and 2030
Figure 8:    Global Autoimmune Disorder Drug Delivery Devices Market (by Region), ($Million), 2019-2030
Figure 2.1:    Global Autoimmune Disorders Drug Delivery Devices Market Segmentation
Figure 3.1:    Global Autoimmune Disorder Drug Delivery Devices Market Methodology
Figure 3.2:    Primary Research Methodology
Figure 3.3:    Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4:    Top-Down Approach (Segment-Wise Analysis)
Figure 4.1:    Key Milestones in History of Syringes
Figure 4.2:    Advancements in Injectable Drug Delivery Technology
Figure 4.3:    Global Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 5.1:    Global Autoimmune Disorder Drug Delivery Devices Market: Regulatory Landscape
Figure 5.2:    FDA 510(k) Approval Timeline
Figure 5.3:    Health Canada Class II-Medical Device Approval Process
Figure 5.4:    European Commission Class IIa-Medical Device Approval Process
Figure 5.5:    National Medical Products Administration Class III-Medical Device Approval Process
Figure 5.6:    Pharmaceutical and Medical Devices Agency (PMDA) Class II-Medical Device Approval Process
Figure 5.7:    Central Drug Standard Control Organization (CDSCO) Class B-Medical Device Approval Process
Figure 6.1:    Number of Patents Filed, Autoimmune Disorders Drug Delivery Devices, January 2017-December 2019
Figure 6.2:    Patent Analysis (by IPC Code)
Figure 6.3:    Patent Analysis (by Country)
Figure 6.4:    Patent Analysis (by Company)
Figure 7.1:    Impact Analysis
Figure 7.2:    Global Prevalence of Rheumatoid Arthritis (1990-2017)
Figure 7.3:    Technological Advancements in Pre-Filled Syringes Over Time
Figure 7.4:    Global Geriatric Population (by Age)
Figure 7.5:    Analysis of Origin of Drugs to Treat Autoimmune Disorders
Figure 7.6:    Opportunity Areas for Injectable Drug Delivery Devices
Figure 8.1:    Global Autoimmune Disorder Drug Delivery Devices Market, by Indication
Figure 8.2:    Global Autoimmune Disorder Drug Delivery Devices Market (by Indication), ($Million), 2019 and 2030
Figure 8.3:    Global Autoimmune Disorder Drug Delivery Devices Market (by Rheumatoid Arthritis), ($Million), 2019-2030
Figure 8.4:    Rheumatoid Arthritis Drug Delivery Devices Market (By Therapeutics), ($Million), 2017-2019
Figure 8.5:    Global Autoimmune Disorder Drug Delivery Devices Market (by Psoriasis), ($Million), 2019-2030
Figure 8.6:    Psoriasis Drug Delivery Devices Market (by Therapeutics), ($Million),  2017-2019
Figure 8.7:    Global Autoimmune Disorder Drug Delivery Devices Market (by Multiple Sclerosis), ($Million), 2019-2030
Figure 8.8:    Multiple Sclerosis Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 8.9:    Global Autoimmune Disorder Drug Delivery Devices Market (by Inflammatory Bowel Diseases), ($Million), 2019-2030
Figure 8.10:    Inflammatory Bowel Diseases Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 8.11:    Global Autoimmune Disorder Drug Delivery Devices Market (Systemic Lupus Erythematosus), ($Million), 2019-2030
Figure 8.12:    Systemic Lupus Erythematosus Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 9.1:    Revenue Contribution of Different Products, 2019 and 2030
Figure 9.2:    Global Autoimmune Disorder Drug Delivery Devices Market (Pen Injectors), ($Million), 2019-2030
Figure 9.3:    Pen Injector based Autoimmune Disorder Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 9.4:    Global Autoimmune Disorder Drug Delivery Devices Market (Auto-injectors), ($Million), 2019-2030
Figure 9.5:    Auto-Injector based Autoimmune Disorder Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 9.6:    Global Autoimmune Disorder Drug Delivery Devices Market (Pre-filled Syringes), ($Million), 2019-2030
Figure 9.7:    Pre-filled Syringes based Autoimmune Disorder Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 9.8:    Global Autoimmune Disorder Drug Delivery Devices Market (Vials), ($Million), 2019-2030
Figure 9.9:    Vials based Autoimmune Disorder Drug Delivery Devices Market (by Therapeutics), ($Million), 2017-2019
Figure 10.1:    Global Autoimmune Disorder Drug Delivery Devices Market (by Manufacturing Type), ($Million), 2019 and 2030
Figure 10.2:    Global Autoimmune Disorder Drug Delivery Devices Market (by In-house Manufacturing), ($Million), 2019-2030
Figure 10.3:    Global Autoimmune Disorder Drug Delivery Devices Market (by Outsourced Manufacturing), ($Million), 2019-2030
Figure 11.1:    Global Autoimmune Disorder Drug Delivery Devices Market (by Region)
Figure 11.2:    Global Autoimmune Disorder Drug Delivery Devices Market (by Region), ($Million), 2019-2030
Figure 11.3:    North America Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.4:    North America: Market Dynamics
Figure 11.5:    Revenue Contributions of Different Countries in North America, ($Million), 2019 and 2030
Figure 11.6:    U.S. Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.7:    Canada Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.8:    Europe Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.9:    Europe: Market Dynamics
Figure 11.10:    Revenue Contributions Different Countries in Europe, ($Million), 2019 and 2030
Figure 11.11:    Germany Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.12:    U.K. Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.13:    France Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.14:    Italy Autoimmune Disorder Drug Delivery Devices Market, ($Million),  2019-2030
Figure 11.15:    Spain Autoimmune Disorder Drug Delivery Devices Market, ($Million),  2019-2030
Figure 11.16:    Rest-of-Europe Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.17:    Asia-Pacific Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.18:    APAC: Market Dynamics
Figure 11.19:    Revenue Contributions Different Countries in Asia-Pacific, ($Million), 2019 and 2030
Figure 11.20:    China Autoimmune Disorder Drug Delivery Devices market, ($Million), 2019-2030
Figure 11.21:    Japan Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.22:    India Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.23:    South Korea Autoimmune Disorder Drug Delivery Devices Market, ($Million),  2019-2030
Figure 11.24:    Australia Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.25:    RoAPAC Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.26:    Latin America Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.27:    Latin America: Market Dynamics
Figure 11.28:    Revenue Contributions of Different Countries in Latin America, ($Million),  2019 and 2030
Figure 11.29:    Brazil Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.30:    Mexico Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.31:    Rest-of-Latin America Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 11.32:    RoW Autoimmune Disorder Drug Delivery Devices Market, ($Million), 2019-2030
Figure 12.1:    Share of Key Developments and Strategies, September 2017-September 2020
Figure 12.2:    Regulatory and Legal Developments Share (by Company), September 2017- September 2020
Figure 12.3:    Partnerships, Alliances, and Business Expansions (by Company),  September 2017-September 2020
Figure 12.4:    Mergers and Acquisitions Share (by Company), September 2017-September 2020
Figure 12.5:    Market Share Analysis (by Companies), 2018 and 2019
Figure 13.1:    Total Number of Companies Profiled
Figure 13.2:    Amgen Inc.: Overall Product Portfolio
Figure 13.3:    Amgen Inc.: Overall Financials, 2017-2019
Figure 13.4:    Amgen Inc.: Revenue (by Region), 2017-2019
Figure 13.5:    Amgen Inc.: R&D Expenditure, 2017-2019
Figure 13.6:    Amgen Inc.: SWOT Analysis
Figure 13.7:    AbbVie Inc.: Overall Product Portfolio
Figure 13.8:    AbbVie Inc.: Overall Financials, 2017-2019
Figure 13.9:    AbbVie Inc.: Revenue (by Region), 2017-2019
Figure 13.10:    AbbVie Inc.: R&D Expenditure, 2017-2019
Figure 13.11:    AbbVie Inc.: SWOT Analysis
Figure 13.12:    Bayer AG: Overall Product Portfolio
Figure 13.13:    Bayer AG: Overall Financials, 2017-2019
Figure 13.14:    Bayer AG: Revenue (by Segment), 2018-2019
Figure 13.15:    Bayer AG: Revenue (by Region), 2017-2019
Figure 13.16:    Bayer AG: R&D Expenditure, 2017-2019
Figure 13.17:    Bayer AG: SWOT Analysis
Figure 13.18:    Biogen Inc.: Overall Service Portfolio
Figure 13.19:    Biogen Inc.: Overall Financials, 2017-2019
Figure 13.20:    Biogen Inc.: Sales (by Product), 2017-2019
Figure 13.21:    Biogen Inc.: Sales (by Region), 2017-2019
Figure 13.22:    Biogen Inc.: R&D Expenditure, 2017-2019
Figure 13.23:    Biogen Inc.: SWOT Analysis
Figure 13.24:    Bristol Myers Squibb Company: Overall Product Portfolio
Figure 13.25:    Bristol Myers Squibb Company: Overall Financials, 2017-2019
Figure 13.26:    Bristol Myers Squibb Company: Revenue (by Region), 2017-2019
Figure 13.27:    Bristol Myers Squibb Company: R&D Expenditure, 2017-2019
Figure 13.28:    Bristol Myers Squibb Company: SWOT Analysis
Figure 13.29:    Eli Lilly & Company: Product Portfolio
Figure 13.30:    Eli Lilly & Company: Pipeline Product Portfolio
Figure 13.31:    Eli Lilly & Company: Overall Financials, 2017-2019
Figure 13.32:    Eli Lilly & Company: Revenue (by Region), 2017-2019
Figure 13.33:    Key Insights About Financial Health of the Company
Figure 13.34:    Eli Lilly & Company: SWOT Analysis
Figure 13.35:    F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 13.36:    F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 13.37:    F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
Figure 13.38:    F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 13.39:    F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 13.40:    F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 13.41:    GlaxoSmithKline plc: Pipeline Product Portfolio
Figure 13.42:    GlaxoSmithKline plc: Overall Financials, 2017-2019
Figure 13.43:    GlaxoSmithKline plc: Revenue (by Segment), 2017-2019
Figure 13.44:    GlaxoSmithKline plc: Revenue (by Region), 2017-2019
Figure 13.45:    GlaxoSmithKline plc: R&D Expenditure, 2017-2019
Figure 13.46:    GlaxoSmithKline plc: SWOT Analysis
Figure 13.47:    Johnson & Jonson Services, Inc.: Product Portfolio
Figure 13.48:    Johnson & Jonson Services, Inc.: Pipeline Products Portfolio
Figure 13.49:    Johnson & Johnson Services, Inc. Company: Overall Financials, 2017-2019
Figure 13.50:    Johnson & Johnson Services, Inc. Company: R&D Expenditure, 2017-2019
Figure 13.51:    Johnson & Johnson Services, Inc.: SWOT Analysis
Figure 13.52:    Merck KGaA: Product Portfolio
Figure 13.53:    Merck KGaA: Overall Financials, 2017-2019
Figure 13.54:    Merck KGaA: Revenue (by Segment), 2017-2019
Figure 13.55:    Merck KGaA: Revenue (by Region), 2017-2019
Figure 13.56:    Merck KGaA: R&D Expenditure, 2017-2019
Figure 13.57:    Merck KGaA: SWOT Analysis
Figure 13.58:    Novartis AG:  Products Portfolio
Figure 13.59:    Novartis AG: Pipeline Products Portfolio
Figure 13.60:    Novartis AG: Overall Financials, 2017-2019
Figure 13.61:    Novartis AG Net Revenue (by Business Segment), 2017-2019
Figure 13.62:    Novartis AG: Net Revenue (by Region), 2017-2019
Figure 13.63:    Novartis AG: R&D Expense, 2017-2019
Figure 13.64:    Novartis AG: SWOT Analysis
Figure 13.65:    Sanofi S.A.: Overall Product Portfolio
Figure 13.66:    Sanofi S.A.: Overall Financials, 2017-2019
Figure 13.67:    Sanofi S.A.: Revenue (by Segment), 2017-2019
Figure 13.68:    Sanofi S.A.: Revenue (by Region), 2017-2019
Figure 13.69:    Sanofi S.A.: R&D Expenditure, 2017-2019
Figure 13.70:    Sanofi S.A.: SWOT Analysis
Figure 13.71:    Teva Pharmaceutical Industries Ltd.: Overall Product Portfolio
Figure 13.72:    Teva Pharmaceutical Industries Ltd.: Overall Financials, 2017-2019
Figure 13.73:    Teva Pharmaceutical Industries Ltd.: Net Revenue (by Business Segment),  2017-2019
Figure 13.74:    Teva Pharmaceutical Industries Ltd.: Research and Development Expense,  2017-2019
Figure 13.75:    Teva Pharmaceutical Industries Ltd.: SWOT Analysis
Figure 13.76:    UCB Pharma SA: Overall Product Portfolio
Figure 13.77:    UCB Pharma SA: Overall Product Portfolio
Figure 13.78:    UCB Pharma SA: Overall Financials, 2017-2019
Figure 13.79:    UCB Pharma SA: Revenue (by Product), 2017-2019
Figure 13.80:    UCB Pharma SA: Revenue (by Region), 2017-2019
Figure 13.81:    UCB Pharma SA: R&D Expenditure, 2017-2019
Figure 13.82:    UCB Pharma SA: SWOT Analysis

FAQ's

What is the Projected Market Size of the Global Autoimmune Disorder Drug Delivery Devices Market by 2030?

Answer – From a market value of $1.69 billion in 2019, the global market for autoimmune disorder drug delivery devices is estimated to reach the mark of $10.67 billion by the end of 2030.

What are Business Drivers that Support the Growth of Aautoimmune Disorder Drug Delivery Devices Market?

Answer – Factors such as the increased prevalence of autoimmune disorders, technological advancements in the field of pre-filled syringes, rising geriatric population, and the surge of biosimilars and biologics in the pharmaceutical market, influence the growth curve of the global autoimmune disorder drug delivery devices market

What Strategies are Adopted by Companies to Expand their Market Footprint in this Sector?

Answer – The exponential rise in the adoption of self-injection devices for the treatment of autoimmune disorders has created a buss among companies to invest in the development of novel autoimmune disorder drug delivery devices.

Which Region Occupies the Largest Share (in Terms of Revenue) in the Global Autoimmune Disorder Drug Delivery Devices Market?

Answer – Based on region, the North American region dominates the global market due to its improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions.

Which Companies are Key Contributors in the Autoimmune Disorder Drug Delivery Devices Market?

Answer – Prominent market players involved include Amgen Inc., AbbVie Inc., Bayer AG, Biogen Inc., Eli Lilly & Company, GSK PLC, Merck KGaA, and Teva Pharmaceutical Industries Ltd., among others.

You may also like

Published Year: 2018

Global Injectable Drug Delivery Market : Focus on Devices, Competitive Landscape and Country - Analy

The global injectable drug delivery market was estimated at $16.73 billion in 2016 and is...

 

Global Autoimmune Disorder Drug Delivery Devices Market

Focus on Product Type, Indication, Manufacturing Type, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030